Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


From Lactocore With Love – An Intranasal Peptide Therapy Candidate For Mental Health

Seeks $5.5m Funding

Executive Summary

US-based biotech Lactocore is developing novel peptides derived from milk as potential treatments for psychiatric, metabolic and cognitive disorders ranging from anxiety and Parkinson’s to obesity and diabetes. CEO and co-founder Anton Malyshev talks to Scrip on the assets, funding and more.

Naturally occurring peptides help our bodies fight bacteria and promote wound healing, with creatine and collagen peptides boosting muscle growth or repair. It’s not surprising then, that therapeutics derived from peptides have been gaining currency as safe and effective alternatives to synthetic drugs.

US-based Lactocore group, with operations in Russia too, has identified certain milk peptides, through a proprietary technology platform, that it aims to develop as treatments for psychiatric, metabolic and cognitive disorders ranging from anxiety and Parkinson’s to obesity and diabetes.

With intra-nasal dosage forms, the company hopes to reduce the physical discomfort and hassle of hospital/clinic visits patients currently undergo for intracutaneous administration of injections.

In an interview with Scrip, CEO Anton Malyshev, who has a Ph.D. in neuroscience, spoke about the lead asset LCGA-17 which is at the pre-Investigational New Drug stage and has potential for indications in mental health like anxiety and post-traumatic stress disorder.

The start-up co-founder also mentioned plans to raise $5.5m in funds from venture capital and angel investors apart from detailing techniques used by the company to address intrinsic weaknesses of naturally occurring peptides like poor chemical and physical stability and a short circulating plasma half-life.

Time Stamps


0:11 Introduction

0:44 An idea is born

3:22 $3.5m seed round funding, plans to raise $5.5m

6:23 Has Theranos impacted the image of start-ups?

8:06 Milk peptide benefits, production techniques

11:47 Potential markets, regulatory environment

15:17 LCGA-17, CHM-273, LCGM-10 Assets

24:39 Addressing peptide stability and half-life

27:36 Partners for CMC supplies, toxicity, PK/PD studies 

33:03 Phase I trial plans for lead compound

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.    

Related Stories$955m-To-Back-Life-Science-Companies


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts